TriSalus Life Sciences (TLSI) Accounts Payables (2020 - 2026)

TriSalus Life Sciences' Accounts Payables history runs 7 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 50.82% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 50.82% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 32.01% from the prior year.
• Accounts Payables advanced to $4.2 million in Q1 2026 per TLSI's latest filing, from $3.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.9 million in Q4 2022 and bottomed at $765244.0 in Q2 2022.
• The 5-year median for Accounts Payables is $2.3 million (2024), against an average of $2.4 million.
• Across the five-year window, Accounts Payables surged 367.75% in 2022 and plunged 32.94% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $4.9 million in 2022, then tumbled by 31.45% to $3.4 million in 2023, then plunged by 32.94% to $2.3 million in 2024, then jumped by 32.01% to $3.0 million in 2025, then surged by 40.97% to $4.2 million in 2026.
• Per Business Quant, the three latest TLSI Accounts Payables figures stand at $4.2 million (Q1 2026), $3.0 million (Q4 2025), and $3.8 million (Q3 2025).